CCL20 thus allows the recruitment of CCR6+ CD4 immunosuppressive T cells (Th17, Treg) at the tumor site and favors the migration and the metastatic potential of CCR6-expressing cancer cells from diverse types [101]. The gene discussed is CCL20; the disease is neoplasm.